267 related articles for article (PubMed ID: 33095287)
1. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
5. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.
Balis FM; Thompson PA; Mosse YP; Blaney SM; Minard CG; Weigel BJ; Fox E
Cancer Chemother Pharmacol; 2017 Jan; 79(1):181-187. PubMed ID: 28032129
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Bowers DC; Aquino VM; Leavey PJ; Bash RO; Journeycake JM; Tomlinson G; Mulne AF; Haynes HJ; Winick NJ
Pediatr Blood Cancer; 2004 Jan; 42(1):93-8. PubMed ID: 14752800
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
13. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
[TBL] [Abstract][Full Text] [Related]
14. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
15. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.
Alexander S; Kraveka JM; Weitzman S; Lowe E; Smith L; Lynch JC; Chang M; Kinney MC; Perkins SL; Laver J; Gross TG; Weinstein H
Pediatr Blood Cancer; 2014 Dec; 61(12):2236-42. PubMed ID: 25156886
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
17. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Mascarenhas L; Felgenhauer JL; Bond MC; Villaluna D; Femino JD; Laack NN; Ranganathan S; Meyer J; Womer RB; Gorlick R; Krailo MD; Marina N
Pediatr Blood Cancer; 2016 Mar; 63(3):493-8. PubMed ID: 26579879
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]